Printer Friendly

SYNTRAIN: Targeting SYNthetic lethal interactions for new cancer treatments TRAINing network.

Project reference: 722729

Duration: From 2016-09-01 to 2020-08-31, ongoing project

Total cost: EUR 3 990 269,16

EU contribution: EUR 3 990 269,16

Objective: Breast and ovarian cancer constitute serious health challenges in the EU. To identify new improved cancer therapeutic approaches, we will pursue a multi-facetted synthetic lethal approach, which takes advantage of the inherent genetic instability of cancer cells. Most mutations acquired by cancer cells do not cause lethality, but the very same mutations may cause cell death when a second gene in a redundant pathway is inactivated. Thus, targeting a gene that is synthetic lethal together with a cancer-specific mutation will kill only cancer cells while sparing normal cells. Synthetic lethal approaches have been clinically pioneered by members of our consortium, by combining cancer-promoting mutations (e.g. in BRCA2) with inactivating combinations of DNA repair genes. We will use this approach as the scientific frame for our ETN (SYNTRAIN) consisting of 9 academic and 1 SME beneficiary as well as 3 partners. We aim to identify synthetic lethal interactions and exploit them to innovate future breast and ovarian cancer treatments through compound screening and development. SYNTRAIN consists of World leading researchers with complementary knowledge in genome maintenance and stress response pathways, and a critical mass of expertise for providing an excellent training in screening methodologies, mechanistic investigations, and drug discovery. We will offer a structured training program that exceeds the capacities of each individual member. We will educate a future generation of cancer researchers with a high innovative capacity and skills that enhances their career prospects in both academia and industry. Our aims are to train young researchers: i) in techniques preparing for a career in cancer research, ii) in complementary skills relevant for work in academia and the pharma industry and iii) to become creative and entrepreneurial, capable of bridging the gap between basic and applied research.

Participants:

IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE

ItalyEU contribution: EUR 258 061,32

VIA ADAMELLO 16

20139 MILANO

Italy

PANEPISTIMIO PATRON

GreeceEU contribution: EUR 242 386,92

UNIVERSITY CAMPUS RIO PATRAS

265 04 RIO PATRAS

Greece

KAROLINSKA INSTITUTET

SwedenEU contribution: EUR 527 318,64

Nobels Vag 5

17177 STOCKHOLM

Sweden

KRAEFTENS BEKAEMPELSE

DenmarkEU contribution: EUR 290 081,88

STRANDBOULEVARDEN 49

2100 KOEBENHAVN

Denmark

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United KingdomEU contribution: EUR 546 575,76

University Offices, Wellington Square

OX1 2JD OXFORD

United Kingdom

UNIVERSITE DE GENEVE

SwitzerlandEU contribution: EUR 265 226,76

RUE DU GENERAL DUFOUR 24

1211 GENEVE

Switzerland

STICHTING HET NEDERLANDS KANKER

Project completion date : 2020-08-31 12:00:00

Major organization : KOBENHAVNS UNIVERSITET

Address : NORREGADE 10

1165 KOBENHAVN

Denmark

Country :Denmark

Financier : EUROPEAN UNION (EU),

Financier address : European Union (EU)

Rue de la Loi 200/Wetstraat 200,

B-1049 Bruxelles/Brussels,

Belgium

Tel: 32-2-2999696, 2993085

Fax: 32-2-2961749

Url: ec.europa.eu/

[c] 2016 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
COPYRIGHT 2016 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Oct 17, 2016
Words:484
Previous Article:INDEED: Innovative Nanowire DEvicE Design.
Next Article:dReDBox: Disaggregated Recursive Datacentre-in-a-Box.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters